Searchable abstracts of presentations at key conferences in endocrinology

ea0035p924 | Pituitary Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>) | ECE2014

GH Deficiency in HIV-infected patients compared to hypopituitary patients

Diazzi Chiara , Brigante Giulia , Ferrannini Giulia , Guaraldi Giovanni , Ansaloni Anna , Simoni Manuela , Rochira Vincenzo

Introduction: Growth Hormone deficiency (GHD) is frequent in patients with human immunodeficiency virus 1 (HIV-1), undergoing highly active antiretroviral therapy. GHD seems to depend on HIV-related lipodystrophy and to be less frequent in women.Aim of the study: To investigate the association of gender, body composition and GH/IGF1 axis, and to clarify whether GHD in HIV-infected patients is functional or a clinical entity.Methods...

ea0032p881 | Pituitary – Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>) | ECE2013

Effects of gender and body composition on GH response to GHRH+Arg in HIV-lipodystrophic patients: higher rate of GH deficiency in men

Brigante Giulia , Diazzi Chiara , Ferrannini Giulia , Ansaloni Anna , Zirilli Lucia , Guaraldi Giovanni , Rochira Vincenzo

Background: SUB:Pituitary – Clinical (Generously supported by IPSEN)GH response to GHRH+Arg is impaired in HIV-infected men and women, compared to gender matched controls. Moreover, reduced GH secretion seems to occur more frequently in HIV-infected males than females.Methods: To determine gender effects on GH secretion in HIV-infected patients with lipodystrophy, we compared GH/IGF1 status and body composition in 103 males and 97 females. ...

ea0032p84 | Bone and Osteoporosis | ECE2013

Effects of treatment for acromegaly on bone mineral density: is pegvisomant protective on lumbar BMD?

Brigante Giulia , Santi Daniele , Diazzi Chiara , De Vincentis Sara , Ferrannini Giulia , Madeo Bruno , Carani Cesare , Simoni Manuela , Rochira Vincenzo

Background: GH–IGF1 status is important for bone health. Acromegaly affects bone status, but less is known on the role of treatments for acromegaly on bone mineral density (BMD). Pegvisomant (Peg) is effective in treating acromegaly by reducing IGF1. As serum GH is not influenced by Peg, it is not known if residual, direct GH effects on bone (not IGF1 mediated) are preserved during treatment.Methods: To evaluate the effects of Peg on BMD, we compare...